周疗法紫杉醇脂质体联合方案治疗晚期胃癌的临床疗效比较

摘要

Objective The clinical effect of Paclitaxel liposome for weeks therapy of advanced gastric carcinoma was analyzed and compared. Methods 82 patients with advanced gastric cancer hospitalized from October 2011~October 2013 ere randomly divided into control group and experimental group, each group has 41 cases, control group was treated with paclitaxel, the experimental group was treated with paclitaxel liposome. Results The experimental group efficiency rate reached 46.34%, benefit rate reached 87.80%, the control group efficient rate was 29.27%, benefit rate was 65.85%, the differences was statistically significant (P<0.05). Conclusion Patients with advanced gastric cancer use weeks treatment of paclitaxel liposome has obvious clinical efficacy, low rate adverse reactions and small toxic effect.%目的：对周疗法紫杉醇脂质体联合方案治疗晚期胃癌的临床疗效进行分析和比较。方法资料选自2011年10月～2013年10月在我院住院治疗的晚期胃癌患者82例，随机分为对照组和实验组，每组各41例，对照组行周疗法普通的紫杉醇联合方案治疗，实验组在对照组基础上行周疗法紫杉醇脂质体联合方案治疗，对两组患者不同的临床疗效与毒副反应进行分析与比较。结果经不同治疗方式的有效实施，两组患者的临床症状均得到了不同程度的改善，实验组有效率达到了46.34%，受益率达到了87.80%，明显优于对照组有效率29.27%，受益率65.85%，两者之间的临床治疗疗效比较差异具有统计学意义（P ＜0.05）。结论晚期胃癌患者行周疗法紫杉醇脂质体联合方案治疗，不仅出现不良反应的程度相对较低，且毒性反应也非常小，患者对于自身临床疗效感到十分满意，同时在一定程度上提升了患者及其家属的生活质量，对于缓解患者的痛苦具有明显的临床功效。